Latest News

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Johnson & Johnson spotlights contrast-driven cataract outcomes at AAO 2026, touting TECNIS PureSee/Odyssey data, 1M implants, and SmartLOAD injector sustainability.

Arun C. Gulani, MD, applies his keratoconus classification to cross-linking, rings, transplant, lens surgery, and staged care.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.

Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.

In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.

An association has been identified between primary open-angle glaucoma and erectile dysfunction.

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

Himani Goyal, MD, reviews a patient case and discusses what a multispecialty group is seeing in practice.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.